About us Career Contact us
 Location:Home>About us




GIBH Profile

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (abbreviated as "GIBH") is jointly established by Chinese Academy of Sciences, Guangdong Province People's Government and Guangzhou Municipal People's Government, it is a scientific research institute focusing on the studies of stem cell and regenerative medicine, chemical biology, infection and immunity, public health and scientific research equipment development. In Mars 2006, the founding of GIBH was officially approved by Central Institutional Organization Commission, and it is a new research and development institute jointly established, managed and owned by Chinese Academy of Sciences with the local government.

Aimed to satisfy human health demands and explore the cutting-edge technologies of life science, GIBH is engaged in the studies on life process and disease mechanism to provide solutions to the innovation and integration of human health and disease prevention, constructing innovative R&D base for China’s bio-medicine and health and serving national strategic demands and regional economic and social development. 

Currently, GIBH has established four core research units: South China Stem Cell and Regenerative Medicine Institute, Chemical Biological Institute, Infection and Immunity Center, as well as Public Health Institute and Drug Discovery Pipeline Core Transformation Unit. In the meantime, by relying on the core research units, it established Respiratory Disease National Key Laboratory (jointly established by Guangzhou Respiratory Disease Institute), CAS Regenerative Medicine Key Laboratory, Guangdong Province Stem Cell and Regenerative Medicine Key Laboratory, and Guangdong Province Biomedical Computing Key Laboratory.

GIBH has a total number of 363 employees, 286 of whom are on-campus investigators, and the young professionals of science and technology aged under 35 account for 67.8%; besides, GIBH owns 56 full-time senior scientific research personnel (including those with a high professional title and those with an associate high professional title, 90% are hired from overseas including nine non-Chinese scientists), four in the Central Organization Department Yong Talent Plan and three winners of “National Excellent Young Scholar Fund”, six National Major Scientific Study Plan Chief Scientists, three national high-end foreign experts, one winner with the title of Middle-aged and Young Innovative Leading Talent, one “Ten Thousand” Young Top-Notch Talent, 18 winners with the CAS “Hundred Talents Program”, one Country Excellent Young Scientist, three “South Guangdong Hundred Talents”, four winners with a title of Guangdong Province Excellent Youth, four winners with the title of Guangdong Province Leading Talent, and  one team win the title of Guangdong Province Innovation Award.

GIBH undertakes important projects funded by National Natural Science Foundation, CAS, Guangdong Province and Guangzhou. Among them, six are national major research plan projects, one is national key R&D plan project, one is CAS Strategic Priority Research Program (class A), one is national major scientific research device and equipment development project, and one is National Natural Science Foundation Innovative Study. Currently, GIBH has published 1110 papers, among which: 964 are included into SCI, 10 are Nature series academic papers, and five are Cell series academic papers; 467 patent applications are filed, among which 380 are domestic patents, 49 are international patents, 38 are PCTs, and 208 are authorized (193 authorized domestic patents and 15 authorized international patents). GIBH won National Natural Science Award Second Prize once, Guangdong Province Science and Technology Award First Prize three times, and Guangzhou Science and Technology Award First Prize three times. 

GIBH emphasizes the institute-local cooperation and result industrialization and attempts to takes the leading role in the development of bio-medical industry. It co-established “CAS Guangzhou Bio-Medical Industry Technical Innovation and Enterprise Incubation Center” in Guangzhou Economic and Technological Development Zone, “Traditional Chinese Medicine Bio-Technology Industrial Center” with Nanhai District, Foshan; from 2013, it started to act as the Vice Director Unit of “South China New Drug Development Center”.

GIBH takes the initiative to boost the international exchange and cooperation, establishes a cooperation relationship with Max Planck Society, University of Auckland and the University of Hong Kong. Until now, GIBH has successfully held “Guangzhou International Stem Cell and Regenerative Medicine Forum” for nine times, which attracted scholars such as Nobel winners to attend and make speech. In 2016, GIBH Hong Kong Center and Guangdong-Hong Kong Stem Cell and Regenerative Medicine Center (Hong Kong) settled in Hong Kong Science Park, at the same time, GIBH collaborated with Max Planck Society and established the “Regeneration Medicine Joint Research Center” which is the first international research center established by Max Planck in China.


Message From The Director 

Stay True to The Mission, and Forge Ahead 

Spring returns to the earth and everything looks fresh! At the occasion of bidding farewell to the old and ushering in the new, on behalf of the leadership, I give my sincere greetings to the staffs, students, retirees and all leaders and friends of people from all social circles that care for and support the development of CAS GIBH! 

In 2016, all efforts are not made for nothing. 

At the outset of "Thirteenth Five-Year" Plan', under the leadership of CAS, Guangdong Province and Guangzhou City, GIBH closely focused on the "One-Three-Five" strategic plan with the joint effort of all employees and students and in the principle of "taking the lead in action" and dared to innovate and make plans while being down-to-earth and being brave enough to struggle, and finally achieved considerable progress in the careers. 

During the past year, we made joint efforts to innovate and achieved new progress in scientific research and result transformation. We obtained a batch of national key R&D plan chief projects and was granted the National Natural Science Foundation excellent young science funded projects for consecutive three years; after ten years’ self-development, the “anti-Alzheimer’s disease” class 1.1 new drug obtained the clinical approval; Guangdong Province Regenerative Medicine and Health Laboratory was listed into the first batch of Guangdong Province laboratory construction plan. We are delighted to see that, our young scientific research personnel have become the backbone for GIBH’s science and technology innovation. 

During the past year, we rose abruptly based on its accumulated strength and marched towards a bright future through international cooperation and platform construction. GIBH’s Hong Kong Center and Guangzhou - Hong Kong Stem Cell and Regenerative Medicine Center (Hong Kong) settled in Hong Kong Science Park; the Regeneration Medicine Joint Research Center (Max Plank -GIBH) jointly initiated by GIBH and Max Plank was officially established, which is the first international research center established by Max Plank in China; the construction of the postgraduate apartment with an area of building of 25000 square meters was finished, and all the students settled in smoothly; the decoration of the clinical therapeutic stem cell preparation GMP platform was also completed. We deeply feel that, even the smallest entity has its own brand; even the smallest research unit has huge energy. 

In 2017, just as jade needs to be polished, one needs to go through trials and tribulations to be strong. 

As a Chinese saying goes, a wise man changes as time and event change. Currently, the world is at the stage of the most active innovation, China ushers in the opportunity to climb the peak of world’s science and technology, and GIBH will be faced with new opportunities and challenges. It is worth mentioning that innovation is the gene of our establishment and development and is the source of our future development. No matter whatever the difficulties lie ahead, we can still break open a way through brambles and thorns and march towards with chest out. 

We obtain knowledge by investigation of things through the stimulating influence of a good teacher. In the new year, we will actively respond to President Xi’s call of rolling up our sleeves to work harder in his 2017 New Year’s greetings. Stay true to the mission, and forge ahead. Dare to assume responsibilities and dare to innovate! The officer may not be without breadth of mind and vigorous endurance. 

I wish a happy new year, a good health, happiness at home and everything well to all teachers, students, employees and their family, and friends! Wish we will have a brighter future! 


Duanqin Pei 

Jan. 2017 



By enhancing its capability of local innovation and competency in the field of biomedicine and health, GIBH aims to be a R&D centre specializing in the core technology of pathogenic mechanisms and biomedical and chemical sciences; a platform contributing to the improvement of global biomedicine and relevant industries; a base attracting and cultivating leading talents in international science frontier; and a window in South China for bringing in international cooperation in the field of biomedicine.


Driven by the demands of the Chinese national health and the development of biomedicine, GIBH is dedicated to focusing on leading research in pathogenic mechanisms, technological innovation, and high level integration. Additionally, GIBH seeks to enhance its capability of R&D and commercialization in the fields of biomedicine, vaccines and diagnose in order to promote the development of Chinese and global standard of health care and medicine.

Major Areas of Research Expertise  

Stem Cell and Regenerative Medicine, Chemical Biology, Infection and Immunity.









The Public Instrument Center  

The center accommodates most of GIBH’s instruments, worth a total of 55 million RMB. Instruments include Flow Cytometer, Laser Scanning Confocal Microscope, High Content Screening System, DNA/RNA Synthesizer, Peptide Synthesizer, Biomolecular Interaction Analysis, X-ray Diffractometer, 400MHz and 500MHz Nuclear Magnetic Resonance Spectrometer, Liquid Chromatogram-Mass spectrometry, Gas Chromatography-Mass Spectrometer, high performance centrifugal machines, and PCR Amplifiers. The center opens its service externally after the internal demands are met.

The total value of the instruments at GIBH is worth 110 million RMB, among which there are 91 instruments valued at over 200,000 RMB.


The laboratory Animal Centre  

The centre aims to build a leading platform of laboratory animals by observing the stringent quality control and standard operating procedures in order to perform high quality animal experiments. The center covers an area of 4,400 square meters and provides GIBH research teams with standardized animals, reliable facilities which assist research teams to complete related experiments.

The centre, which is run entirely by ALLAC standards, goes for ALLAC verification and has obtained the certification of qualified laboratory animal facilities and the license for using laboratory animal issued by Guangdong Laboratory Animal monitoring Institute. Recently, the centre has become the largest standard laboratory animal centre in Guangdong Province which has established stable collaborating relationships with the Guangdong Laboratory Animal Monitoring Institute, Shanghai Laboratory Animal Centre of Chinese Academy of Sciences, and many colleges and universities in the Guangdong area.


Copyright ©2002-2008 Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences